BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38828744)

  • 1. Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies.
    Ridgway H; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Hoffmann W; Węgrzyn K; Vassilaki N; Mpekoulis G; Zouridakis M; Giastas P; Vidali VP; Kelaidonis K; Matsoukas MT; Dimitriou M; Mavromoustakos T; Tsiodras S; Gorgoulis VG; Karakasiliotis I; Chasapis CT; Matsoukas JM
    Expert Opin Ther Targets; 2024 May; 28(5):437-459. PubMed ID: 38828744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Existence of Quantum Pharmacology in Sartans: Evidence in Isolated Rabbit Iliac Arteries.
    Gadanec LK; Swiderski J; Apostolopoulos V; Kelaidonis K; Vidali VP; Canko A; Moore GJ; Matsoukas JM; Zulli A
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.
    Kelaidonis K; Ligielli I; Letsios S; Vidali VP; Mavromoustakos T; Vassilaki N; Moore GJ; Hoffmann W; Węgrzyn K; Ridgway H; Chasapis CT; Matsoukas JM
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Density functional theory and enzyme studies support interactions between angiotensin receptor blockers and angiotensin converting enzyme-2: Relevance to coronavirus 2019.
    Apostolopoulos V; Georgiou N; Tzeli D; Mavromoustakos T; Moore GJ; Kelaidonis K; Matsoukas MT; Tsiodras S; Swiderski J; Kate Gadanec L; Zulli A; Chasapis CT; Matsoukas JM
    Bioorg Chem; 2024 Jun; 150():107602. PubMed ID: 38959647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2.
    Ridgway H; Moore GJ; Mavromoustakos T; Tsiodras S; Ligielli I; Kelaidonis K; Chasapis CT; Gadanec LK; Zulli A; Apostolopoulos V; Petty R; Karakasiliotis I; Gorgoulis VG; Matsoukas JM
    Comput Struct Biotechnol J; 2022; 20():2091-2111. PubMed ID: 35432786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System.
    Moore GJ; Ridgway H; Kelaidonis K; Chasapis CT; Ligielli I; Mavromoustakos T; Bojarska J; Matsoukas JM
    Molecules; 2022 Jul; 27(15):. PubMed ID: 35956801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19.
    Moore GJ; Pires JM; Kelaidonis K; Gadanec LK; Zulli A; Apostolopoulos V; Matsoukas JM
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection
    Curreli F; Victor SMB; Ahmed S; Drelich A; Tong X; Tseng CK; Hillyer CD; Debnath AK
    mBio; 2020 Dec; 11(6):. PubMed ID: 33310780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney.
    Jiang X; Eales JM; Scannali D; Nazgiewicz A; Prestes P; Maier M; Denniff M; Xu X; Saluja S; Cano-Gamez E; Wystrychowski W; Szulinska M; Antczak A; Byars S; Skrypnik D; Glyda M; Król R; Zywiec J; Zukowska-Szczechowska E; Burrell LM; Woolf AS; Greenstein A; Bogdanski P; Keavney B; Morris AP; Heagerty A; Williams B; Harrap SB; Trynka G; Samani NJ; Guzik TJ; Charchar FJ; Tomaszewski M
    Eur Heart J; 2020 Dec; 41(48):4580-4588. PubMed ID: 33206176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Two-Way Switch Role of ACE2 in the Treatment of Novel Coronavirus Pneumonia and Underlying Comorbidities.
    Pang XC; Zhang HX; Zhang Z; Rinkiko S; Cui YM; Zhu YZ
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
    Wang Y; Takeshita H; Yamamoto K; Huang Y; Wang C; Nakajima T; Nozato Y; Fujimoto T; Yokoyama S; Hongyo K; Nakagami F; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Rakugi H
    FASEB J; 2021 Mar; 35(3):e21419. PubMed ID: 33566370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.